{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:11:37Z","timestamp":1794370297306,"version":"4.9.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00455-5","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T04:07:47Z","timestamp":1736395667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antimelanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort"],"prefix":"10.1186","volume":"9","author":[{"given":"Sai K.","family":"Koyoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Ezzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Wahezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Kumthekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement E.","family":"Tagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi","family":"Ayesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"6","key":"455_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2169\/internalmedicine.1516-18","volume":"58","author":"N Sakamoto","year":"2019","unstructured":"Sakamoto N, Ishimoto H, Nakashima S, Yura H, Miyamura T, Okuno D, et al. Clinical features of Anti-MDA5 antibody-positive Rapidly Progressive interstitial lung disease without signs of Dermatomyositis. Intern Med. 2019;58(6):837\u201341.","journal-title":"Intern Med"},{"issue":"6","key":"455_CR2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","volume":"140","author":"C Cassius","year":"2020","unstructured":"Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A, et al. MDA5(+) Dermatomyositis is Associated with stronger skin type I Interferon Transcriptomic signature with Upregulation of IFN-kappa transcript. J Invest Dermatol. 2020;140(6):1276\u20139. e7.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"455_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12969-021-00574-6","volume":"19","author":"MM Perron","year":"2021","unstructured":"Perron MM, Vasquez-Canizares N, Tarshish G, Wahezi DM. Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies. Pediatr Rheumatol Online J. 2021;19(1):92.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"455_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-019-0871-4","volume":"21","author":"D Li","year":"2019","unstructured":"Li D, Tansley SL. Juvenile dermatomyositis-clinical phenotypes. Curr Rheumatol Rep. 2019;21(12):74.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"455_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","volume":"49","author":"R Nakashima","year":"2010","unstructured":"Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"455_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"455_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25\u201334.","journal-title":"J Am Acad Dermatol"},{"key":"455_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12948-015-0031-y","volume":"13","author":"P Parronchi","year":"2015","unstructured":"Parronchi P, Radice A, Palterer B, Liotta F, Scaletti C. MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations. Clin Mol Allergy. 2015;13:22.","journal-title":"Clin Mol Allergy"},{"issue":"6","key":"455_CR9","first-page":"891","volume":"32","author":"A Ceribelli","year":"2014","unstructured":"Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis. Clin Exp Rheumatol. 2014;32(6):891\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"455_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.21037\/atm.2017.03.94","volume":"5","author":"RD Sontheimer","year":"2017","unstructured":"Sontheimer RD. MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis. Ann Transl Med. 2017;5(7):160.","journal-title":"Ann Transl Med"},{"issue":"1","key":"455_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12969-021-00595-1","volume":"19","author":"TW Yeung","year":"2021","unstructured":"Yeung TW, Cheong KN, Lau YL, Tse KN. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Pediatr Rheumatol Online J. 2021;19(1):103.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"455_CR12","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3899\/jrheum.160024","volume":"43","author":"H Cao","year":"2016","unstructured":"Cao H, Xia Q, Pan M, Zhao X, Li X, Shi R, et al. Gottron Papules and Gottron sign with Ulceration: a distinctive cutaneous feature in a subset of patients with Classic Dermatomyositis and clinically Amyopathic Dermatomyositis. J Rheumatol. 2016;43(9):1735\u201342.","journal-title":"J Rheumatol"},{"issue":"4","key":"455_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","volume":"78","author":"DJB Kurtzman","year":"2018","unstructured":"Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4):776\u201385.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"455_CR14","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s10067-015-2928-8","volume":"35","author":"B Gil","year":"2016","unstructured":"Gil B, Merav L, Pnina L, Chagai G. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol. 2016;35(8):2125\u201330.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"455_CR15","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","volume":"56","author":"Y Abe","year":"2017","unstructured":"Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N. Clinical characteristics and change in the antibody titers of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford). 2017;56(9):1492\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"455_CR16","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013;65(8):1316\u201324.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"455_CR17","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95(1):e70\u20138.","journal-title":"Neurology"},{"key":"455_CR18","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with Anti-MDA5 antibodies: Bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352.","journal-title":"Front Immunol"},{"key":"455_CR19","doi-asserted-by":"crossref","unstructured":"He S, Zhou Y, Fan C, Ma J, Chen Y, Wu W et al. Differences in sex- and age-associated mortality in patients with anti-MDA5 positive Dermatomyositis. Mod Rheumatol. 2022.","DOI":"10.1093\/mr\/roac091"},{"issue":"5","key":"455_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/mus.24566","volume":"51","author":"AR Findlay","year":"2015","unstructured":"Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638\u201356.","journal-title":"Muscle Nerve"},{"issue":"4","key":"455_CR21","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/keaa429","volume":"60","author":"G Mamyrova","year":"2021","unstructured":"Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, et al. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology (Oxford). 2021;60(4):1839\u201349.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"455_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1590\/abd1806-4841.20186803","volume":"93","author":"IB Borges","year":"2018","unstructured":"Borges IB, Silva MG, Shinjo SK. Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis. An Bras Dermatol. 2018;93(4):517\u201323. https:\/\/doi.org\/10.1590\/abd1806-4841.20186803.","journal-title":"An Bras Dermatol"},{"key":"455_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","volume":"23","author":"S Sato","year":"2013","unstructured":"Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23:496\u2013502.","journal-title":"Mod Rheumatol"},{"key":"455_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1378\/chest.08-2740","volume":"136","author":"H Mukae","year":"2009","unstructured":"Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136:1341\u20137.","journal-title":"Chest"},{"key":"455_CR25","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","volume":"26","author":"S Ye","year":"2007","unstructured":"Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647\u201354.","journal-title":"Clin Rheumatol"},{"key":"455_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3760\/cma.j.issn.0366-6999.2010.05.002","volume":"123","author":"SY Ji","year":"2010","unstructured":"Ji SY, Zeng FQ, Guo Q, Tan GZ, Tang HF, Luo YJ. Predictive factors and unfavorable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J (Engl). 2010;123:517\u201322.","journal-title":"Chin Med J (Engl)"},{"key":"455_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/archdermatol.2009.323","volume":"146","author":"RD Sontheimer","year":"2010","unstructured":"Sontheimer RD. Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol. 2010;146:76\u201380.","journal-title":"Arch Dermatol"},{"issue":"3","key":"455_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in north American patients with Dermatomyositis. J Rheumatol. 2017;44(3):319\u201325.","journal-title":"J Rheumatol"},{"issue":"12","key":"455_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11926-018-0798-1","volume":"20","author":"S Moghadam-Kia","year":"2018","unstructured":"Moghadam-Kia S, Oddis CV, Aggarwal R. Anti-MDA5 antibody spectrum in Western World. Curr Rheumatol Rep. 2018;20(12):78.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"455_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","volume":"50","author":"C Lv","year":"2023","unstructured":"Lv C, You H, Xu L, Wang L, Yuan F, Li J, et al. Coexistence of Anti-Ro52 antibodies in Anti-MDA5 antibody-positive dermatomyositis is highly Associated with Rapidly Progressive interstitial lung disease and mortality risk. J Rheumatol. 2023;50(2):219\u201326.","journal-title":"J Rheumatol"},{"issue":"5","key":"455_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22498","volume":"67","author":"NS Narang","year":"2015","unstructured":"Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken). 2015;67(5):667\u201372.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"455_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","volume":"35","author":"X Ma","year":"2016","unstructured":"Ma X, Chen Z, Hu W, Guo Z, Wang Y, Kuwana M, et al. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol. 2016;35(2):489\u201393.","journal-title":"Clin Rheumatol"},{"key":"455_CR33","doi-asserted-by":"crossref","unstructured":"Koga T, Okamoto M, Satoh M, Fujimoto K, Zaizen Y, Chikasue T et al. Positive autoantibody is associated with malignancies in patients with idiopathic interstitial pneumonias. Biomedicines. 2022;10(10).","DOI":"10.3390\/biomedicines10102469"},{"issue":"4","key":"455_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/art.42311","volume":"75","author":"CA Mecoli","year":"2023","unstructured":"Mecoli CA, Igusa T, Chen M, Wang X, Albayda J, Paik JJ, et al. Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population. Arthritis Rheumatol. 2023;75(4):620\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"455_CR35","doi-asserted-by":"publisher","first-page":"2024869","DOI":"10.1155\/2020\/2024869","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li Y, Wu J, Miao M, Gao X, Cai W, Shao M, et al. Predictors of poor outcome of Anti-MDA5-Associated rapidly progressive interstitial lung disease in a Chinese cohort with Dermatomyositis. J Immunol Res. 2020;2020:2024869.","journal-title":"J Immunol Res"},{"issue":"11","key":"455_CR36","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1093\/brain\/awz293","volume":"142","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59.","journal-title":"Brain"},{"issue":"2","key":"455_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.55563\/clinexprheumatol\/brvl1v","volume":"40","author":"RW Hallowell","year":"2022","unstructured":"Hallowell RW, Paik JJ. Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clin Exp Rheumatol. 2022;40(2):373\u201383.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"455_CR38","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","volume":"59","author":"M Shirakashi","year":"2020","unstructured":"Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020;59(11):3284\u201392.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"455_CR39","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","volume":"37","author":"H So","year":"2018","unstructured":"So H, Wong VTL, Lao VWN, Pang HT, Yip RML. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol. 2018;37(7):1983\u20139.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"455_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, Tacrolimus, and Cyclophosphamide in interstitial lung diseases accompanied by Anti-melanoma differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. 2020;72(3):488\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"455_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","volume":"109","author":"T Takada","year":"2015","unstructured":"Takada T, Aoki A, Asakawa K, Sakagami T, Moriyama H, Narita I, et al. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis. Respir Med. 2015;109(9):1174\u201380.","journal-title":"Respir Med"},{"issue":"7","key":"455_CR42","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"455_CR43","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11926-012-0246-6","volume":"14","author":"T Mimori","year":"2012","unstructured":"Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14(3):264\u201374.","journal-title":"Curr Rheumatol Rep"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00455-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:07:10Z","timestamp":1736399230000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00455-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00455-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5085511\/v1","asserted-by":"object"}]},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Montefiore\/Albert Einstein College of Medicine Institutional Review Board. As this retrospective chart review study did not involve any active intervention, the requirement for consent to participate was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}